Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00163527|
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : December 2, 2016
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.
The aim of the study is to investigate the effect of roflumilast taken orally together with low dose inhaled corticosteroids on lung function. Roflumilast will be administered at one dose level once daily together with inhaled corticosteroids at one dose level twice daily. The study duration consists of a baseline period (2 to 6 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: Roflumilast||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2054 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Chronic Asthma|
|Study Start Date :||April 2003|
|Primary Completion Date :||November 2005|
|Study Completion Date :||November 2005|
- change in forced expiratory volume in 1 second from baseline to final visit.
- change from baseline to each visit for spirometry variables, forced vital capacity, mean expiratory flow, peak expiratory flow
- change from baseline to each visit based on diary data variables (asthma symptom scores: daytime, nighttime, and summary, use of rescue medication, diurnal variability)
- number of rescue free/symptom free days based on the diary card
- area under the curves over the full 24-week trial period for the diary variables
- number of exacerbations
- time to first exacerbation
- change from baseline according to the Asthma Quality of Life Questionnaire (AQLQ).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00163527
Show 24 Study Locations
|Study Director:||AstraZeneca AstraZeneca||AstraZeneca|